Maxpro Capital Acquisition (JMAC) Competitors $5.74 +0.29 (+5.32%) As of 07/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. HRTX, BNTC, IVA, CMPS, VOR, OLMA, RCKT, AURA, AVIR, and GLUEShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Heron Therapeutics (HRTX), Benitec Biopharma (BNTC), Inventiva (IVA), COMPASS Pathways (CMPS), Vor Biopharma (VOR), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), Aura Biosciences (AURA), Atea Pharmaceuticals (AVIR), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Its Competitors Heron Therapeutics Benitec Biopharma Inventiva COMPASS Pathways Vor Biopharma Olema Pharmaceuticals Rocket Pharmaceuticals Aura Biosciences Atea Pharmaceuticals Monte Rosa Therapeutics Maxpro Capital Acquisition (NASDAQ:JMAC) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations. Which has more volatility and risk, JMAC or HRTX? Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Which has better valuation and earnings, JMAC or HRTX? Maxpro Capital Acquisition has higher earnings, but lower revenue than Heron Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/AHeron Therapeutics$144.29M2.13-$13.58M-$0.06-33.58 Does the media favor JMAC or HRTX? In the previous week, Maxpro Capital Acquisition and Maxpro Capital Acquisition both had 2 articles in the media. Heron Therapeutics' average media sentiment score of 0.88 beat Maxpro Capital Acquisition's score of 0.71 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maxpro Capital Acquisition 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend JMAC or HRTX? Heron Therapeutics has a consensus price target of $5.00, indicating a potential upside of 148.14%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is JMAC or HRTX more profitable? Maxpro Capital Acquisition has a net margin of 0.00% compared to Heron Therapeutics' net margin of -5.24%. Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A Heron Therapeutics -5.24%N/A -3.43% Do institutionals & insiders believe in JMAC or HRTX? 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 5.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryHeron Therapeutics beats Maxpro Capital Acquisition on 7 of the 10 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$77.08M$206.62M$2.16B$9.26BDividend YieldN/A3.15%2.60%4.03%P/E RatioN/A1.8822.2719.56Price / SalesN/A544.2398.98183.65Price / CashN/A109.2813.3957.93Price / BookN/A8.7273.625.58Net IncomeN/A-$10.64M-$134.41M$257.82M7 Day Performance-10.87%-2.16%-0.42%-0.39%1 Month Performance-5.48%-3.09%0.77%7.80%1 Year Performance2,791.69%96.48%19.97%12.95% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$5.74+5.3%N/A+2,834.6%$77.08MN/A0.002,021HRTXHeron Therapeutics3.5338 of 5 stars$2.23+1.4%$5.00+124.2%-38.4%$335.64M$144.29M-37.17300Gap DownBNTCBenitec Biopharma1.4529 of 5 stars$13.84+9.7%$23.83+72.2%+22.0%$331.28M$80K-9.1720IVAInventiva3.163 of 5 stars$3.37-2.6%$10.40+208.6%+21.4%$330.99M$9.95M0.00100Gap UpCMPSCOMPASS Pathways1.7918 of 5 stars$3.53+2.0%$17.00+381.6%-50.0%$323.73MN/A-1.77120Analyst ForecastAnalyst RevisionVORVor Biopharma3.8627 of 5 stars$2.54+5.8%$5.63+121.6%+130.8%$317.40MN/A-1.54140Gap UpHigh Trading VolumeOLMAOlema Pharmaceuticals2.4252 of 5 stars$4.99+7.8%$24.50+391.0%-65.1%$316.79MN/A-2.4870RCKTRocket Pharmaceuticals4.8391 of 5 stars$3.20+8.1%$18.60+481.3%-87.5%$316.08MN/A-1.22240Gap UpAURAAura Biosciences2.5676 of 5 stars$6.59+5.4%$22.00+233.8%-27.0%$314.18MN/A-3.4750AVIRAtea Pharmaceuticals2.7136 of 5 stars$3.76+3.0%$6.00+59.6%+0.8%$312.79MN/A-2.2870Positive NewsGLUEMonte Rosa Therapeutics2.1704 of 5 stars$5.29+4.5%$15.33+189.9%+24.8%$311.24M$75.62M66.1390 Related Companies and Tools Related Companies HRTX Competitors BNTC Competitors IVA Competitors CMPS Competitors VOR Competitors OLMA Competitors RCKT Competitors AURA Competitors AVIR Competitors GLUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JMAC Stock Alerts